Replies

https://www.inhousepharmacy.vu/ Sure seems a lot less expensive than getting in the states.

Budesonide (Pulmicort) (Flexhaler): [180 mcg/inhalation, 120 inhalations costs $250] Usual dose for asthma is 1-2 puffs BID but if give 4 INH BID x 14 days = 124 doses.

• A multicentre, open-label, multi-arm, randomised, controlled trial shows that inhaled budesonide (800 μg twice daily for 14 days) for patients in the community with suspected COVID-19 and at high risk of complications was associated with improved time to recovery and a reduced chance of hospitalization compared with patients who received usual care (Lancet 2021 Aug 10;EPub Ahead of Print). Eligible participants were aged 65 years or older or 50 years or older with comorbidities ( such as cancer, diabetes, cardiovascular or lung disease, or obesity), and unwell for up to 14 days (average, 6 days) with suspected COVID-19 but not admitted to hospital. There was a benefit in time to first self-reported recovery of an estimated 3 days in the budesonide group versus the usual care group (11.8 days vs 14.7 days). For the hospital admission or death outcome, the estimated rate was 6·8% in the budesonide group versus 8·8% in the usual care group (estimated absolute difference 2.0%). Editorialist notes that ICS is a simple and inexpensive option with little apparent downside, and offering it to select higher-risk patients (similar to those in this trial) would be reasonable.